Panacea Biotec Soars 11.89% to 52-Week High After Launch of EU-Funded DENSTAR Project

Panacea Biotec is having its best week in years. The stock surged 11.89% to a fresh 52-week high of ₹619.05 on June 9, 2026, on the NSE, rallying from a 52-week low of ₹293.10, for an 111% climb in under twelve months. The trigger was the official launch of the DENSTAR project, a 48-month, EU-backed initiative worth €11,091,138.75,. This aimed at advancing the licensure of Panacea Biotec’s dengue vaccine DengiAll in sub-Saharan Africa.

While broader Indian markets struggled, Panacea Biotec outperformed its entire pharma sector in a single session, and the data shows why this is more than a one-day story.

What Is the DENSTAR Project?

The DENSTAR project officially commenced on June 1, 2026. This funded under the Global Health European and Developing Countries Clinical Trials Partnership 3 Joint Undertaking, supported by the European Union. It targets dengue fever, one of the world’s fastest-spreading neglected tropical diseases, with a focus on bringing DengiAll to regulatory approval across Africa. 

Key DENSTAR Project Facts

• The DENSTAR consortium brings together 10 partners from 9 countries, including universities, research organisations, and biotech firms.
• Italy’s Sclavo Vaccines Association, a non-profit dedicated to vaccine R&D in developing nations, coordinates the entire consortium. 
• The project will run Phase I and Phase III clinical studies and evaluate vaccine efficacy against DENV-4 using Controlled Human Infection Models. 
• DengiAll is a single-dose tetravalent dengue vaccine; its licensure in sub-Saharan Africa would mark a major milestone for global dengue prevention. 

Panacea Biotec Stock: Six Sessions, One Direction

Panacea Biotec has gained for six consecutive sessions, accumulating a 55.35% return in that period alone, a sharp divergence from the Sensex. It has been on a three-week losing streak, down 2.1%. The stock is outperforming its Pharmaceuticals and Biotechnology sector by 11.52% in a single day a company-specific move, not a sector rally. 

• The stock trades above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages all timeframes aligned bullishly. 
• Panacea Biotec’s total market capitalisation stands at ₹3,662.79 crore as of June 9, 2026, per NSE data. 
• Trading volumes crossed 3.18 lakh shares on the DENSTAR announcement day, confirming genuine institutional interest. 
• Three-year returns stand at 257.02%, compared to the Sensex’s 18.32% over the same period. 

FY26 Financials: The Other Side of the Story

The stock momentum does not erase fundamental challenges. Panacea Biotec reported a net loss of ₹2,988 lakh for FY26. However, total consolidated income from operations rose to ₹63,977 lakh from ₹55,909 lakh in FY25, a 14.4% revenue increase year-over-year. The DENSTAR project adds a multi-year revenue and milestone pathway that the market is clearly pricing in ahead of clinical results. 

Key Takeaways

• Panacea Biotec hit ₹619.05 on June 9, up 11.89% and a fresh 52-week high
• The stock has gained 55.35% across six consecutive positive sessions
• DENSTAR is a 48-month, €11.09 million EU-funded dengue vaccine licensure project
• The 10-partner, 9-country consortium targets Phase I and III trials for DengiAll in Africa
• Three-year stock return stands at 257.02%, vastly outpacing the Sensex’s 18.32%
• FY26 revenues grew 14.4% to ₹63,977 lakh despite reporting a net loss of ₹2,988 lakh

Panacea Biotec’s DENSTAR launch turns a pipeline asset into a funded, multi-country clinical program, and the market responded immediately. Live NSE price data is available at nseindia.com.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.